CN112041333B - 新型融合蛋白和用于预防或治疗癌症的包含该融合蛋白的药物组合物 - Google Patents

新型融合蛋白和用于预防或治疗癌症的包含该融合蛋白的药物组合物 Download PDF

Info

Publication number
CN112041333B
CN112041333B CN201980028463.XA CN201980028463A CN112041333B CN 112041333 B CN112041333 B CN 112041333B CN 201980028463 A CN201980028463 A CN 201980028463A CN 112041333 B CN112041333 B CN 112041333B
Authority
CN
China
Prior art keywords
leu
ser
thr
val
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201980028463.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN112041333A (zh
Inventor
金廷镐
金范锡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Goodall T Cell Co ltd
Original Assignee
Goodall T Cell Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goodall T Cell Co ltd filed Critical Goodall T Cell Co ltd
Publication of CN112041333A publication Critical patent/CN112041333A/zh
Application granted granted Critical
Publication of CN112041333B publication Critical patent/CN112041333B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980028463.XA 2018-04-26 2019-04-26 新型融合蛋白和用于预防或治疗癌症的包含该融合蛋白的药物组合物 Expired - Fee Related CN112041333B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2018-0048343 2018-04-26
KR20180048343 2018-04-26
PCT/KR2019/005096 WO2019209078A1 (ko) 2018-04-26 2019-04-26 신규한 융합 단백질 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물

Publications (2)

Publication Number Publication Date
CN112041333A CN112041333A (zh) 2020-12-04
CN112041333B true CN112041333B (zh) 2024-06-28

Family

ID=68293649

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980028463.XA Expired - Fee Related CN112041333B (zh) 2018-04-26 2019-04-26 新型融合蛋白和用于预防或治疗癌症的包含该融合蛋白的药物组合物

Country Status (6)

Country Link
US (1) US11820801B2 (enExample)
EP (1) EP3792276A4 (enExample)
JP (1) JP7485368B2 (enExample)
KR (3) KR102194644B1 (enExample)
CN (1) CN112041333B (enExample)
WO (1) WO2019209078A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019309472A1 (en) * 2018-07-24 2021-03-18 Good T Cells, Inc. Composition for preventing or treating immune-related diseases
EP3943107A4 (en) * 2019-03-20 2022-12-07 Good T Cells, Inc. COMPOSITION FOR THE PREVENTION OR TREATMENT OF BRAIN AND NERVOUS SYSTEM DISEASES
CN114929733A (zh) * 2019-11-08 2022-08-19 古德T细胞有限公司 调节性t细胞表面抗原的表位和与其特异性结合的抗体
CN111285936A (zh) * 2020-03-11 2020-06-16 北京双赢科创生物科技有限公司 靶向肿瘤的酸性敏感纳米肽段及其应用
CN122161853A (zh) * 2023-09-06 2026-06-05 古德T细胞有限公司 经亲和力成熟的新型抗体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3827837A1 (en) * 2018-07-24 2021-06-02 Good T Cells, Inc. Composition for preventing or treating immune-related diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
EP1699821B1 (en) * 2003-12-31 2012-06-20 Merck Patent GmbH Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
EP1907582B1 (en) * 2005-07-27 2012-01-04 Oncotherapy Science, Inc. Ect2 as a therapeutic target for esophageal cancer
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
KR100888022B1 (ko) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
CN101687933B (zh) 2007-05-30 2015-11-25 浦项工科大学校产学协力团 免疫球蛋白融合蛋白
CA2695374A1 (en) * 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
CN101891823B (zh) 2010-06-11 2012-10-03 北京东方百泰生物科技有限公司 一种Exendin-4及其类似物融合蛋白
KR101847523B1 (ko) 2011-01-24 2018-05-28 연세대학교 산학협력단 조절자 Ｔ 세포에 특이적으로 존재하는 새로운 표면단백질 Ｌｒｉｇ-1의 용도
US9156897B2 (en) 2012-06-08 2015-10-13 Alkermes, Inc. Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
EP3456734B1 (en) 2012-10-04 2022-01-05 Research Development Foundation Serine protease molecules and therapies
JP6404349B2 (ja) 2013-07-30 2018-10-10 インダストリー−アカデミック コーポレーション ファウンデーション，ヨンセイ ユニバーシティ サクサチリン−Ｆｃ融合タンパク質及びその用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3827837A1 (en) * 2018-07-24 2021-06-02 Good T Cells, Inc. Composition for preventing or treating immune-related diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Fc-Based Cytokines Prospects for Engineering Superior Therapeutics;Jalal A. Jazayeri等;Biodrugs;第22卷(第1期);摘要 *
The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status;Mikael Johansson等;NEURO-ONCOLOGY;第15卷(第9期);第1200页左栏第1-3段以及右栏第1-2段 *

Also Published As

Publication number Publication date
KR102194644B1 (ko) 2020-12-24
WO2019209078A1 (ko) 2019-10-31
JP7485368B2 (ja) 2024-05-16
KR20200144524A (ko) 2020-12-29
CN112041333A (zh) 2020-12-04
US11820801B2 (en) 2023-11-21
EP3792276A1 (en) 2021-03-17
KR20230146491A (ko) 2023-10-19
EP3792276A4 (en) 2022-02-16
JP2021521817A (ja) 2021-08-30
KR20190124665A (ko) 2019-11-05
US20210130422A1 (en) 2021-05-06
KR102754984B1 (ko) 2025-01-21

Similar Documents

Publication Publication Date Title
KR102714455B1 (ko) 이중특이성 재조합단백질 및 이의 응용
KR102754984B1 (ko) 신규한 융합 단백질 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물
CN109575140B (zh) 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途
AU2017202437B2 (en) Novel immunoconjugates
DK3075745T3 (en) Mutated interleukin-2 polypeptides
KR102263643B1 (ko) 면역 관련 질환의 예방 또는 치료용 조성물
CN107835820B (zh) 识别癌症特异性IL13Rα2的CAR T细胞
CN107683289B (zh) IL13Rα2结合剂和其在癌症治疗中的用途
KR101836501B1 (ko) 근육 성장을 증가시키기 위한 조성물 및 방법
CA3087423A1 (en) Anti-claudin 18.2 antibodies
CN109071652B (zh) 包含tnf家族配体三聚体和生腱蛋白结合模块的抗原结合分子
KR20230041819A (ko) Hla-g 항원-결합 도메인을 포함하는 단백질 및 이의 용도
KR20160099087A (ko) 이중특이성 her2 항체 및 사용 방법
KR20230059789A (ko) 항-가변 muc1* 항체 및 이의 용도
TW200823235A (en) Prophylactic and therapeutic agent for cancers
EP4467567A1 (en) Anti-cd70 nanoantibody and use thereof
KR20230137393A (ko) Psma 결합 단백질 및 이의 용도
JP2021521817A5 (enExample)
CN112409484B (zh) 多功能抗体、其制备及其用途
CN117157314A (zh) Pd-l1抗体、融合蛋白及其用途
KR20210017449A (ko) 신규한 융합 단백질 및 이의 용도
RU2830232C2 (ru) Методы профилактики и лечения сердечных заболеваний
CN117186222A (zh) Pd-l1结合分子及其用途
CN118307671A (zh) Pd-1结合分子及其用途
HK1263189A1 (en) Bispecific recombinant protein and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20240628

CF01 Termination of patent right due to non-payment of annual fee